3.56

1.93% -0.07

Iovance Biotherapeutics Inc (IOVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IOVA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.63

Aprire:

$3.59

Volume 24 ore:

8.31M

Relative Volume:

0.92

Capitalizzazione di mercato:

$1.19B

Reddito:

$32.77M

Utile/perdita netta:

$-440.22M

Rapporto P/E:

-2.1317

EPS:

-1.67

Flusso di cassa netto:

$-400.48M

1 W Prestazione:

+0.56%

1M Prestazione:

-32.32%

6M Prestazione:

-62.96%

1 anno Prestazione:

-75.98%

Intervallo 1D:

$3.51

$3.64

Intervallo di 1 settimana:

$3.33

$3.69

Portata 52W:

$3.33

$14.77

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Nome

Iovance Biotherapeutics Inc

Settore

Healthcare (1166)

Industria

Biotechnology (671)

Telefono

(650) 260-7120

Indirizzo

825 INDUSTRIAL ROAD, SAN CARLOS

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

IOVA's Discussions on Twitter

Confronta IOVA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IOVA Iovance Biotherapeutics Inc	3.56	1.19B	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	492.69	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	637.36	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	589.15	35.93B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	268.46	34.75B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	267.39	28.24B	3.81B	-644.79M	-669.77M	-6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-24	Iniziato	UBS	Buy
2024-07-29	Downgrade	Piper Sandler	Overweight → Neutral
2023-11-20	Iniziato	Goldman	Buy
2023-09-18	Reiterato	Barclays	Overweight
2023-05-30	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-27	Ripresa	Wells Fargo	Equal Weight
2023-01-27	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-12-09	Downgrade	Goldman	Buy → Neutral
2022-10-31	Iniziato	Guggenheim	Neutral
2022-08-18	Ripresa	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Stifel	Hold → Buy
2021-12-07	Ripresa	Cowen	Outperform
2021-06-10	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Downgrade	Piper Sandler	Overweight → Neutral
2021-05-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Downgrade	Stifel	Buy → Hold
2021-05-03	Iniziato	Truist	Buy
2021-04-16	Iniziato	Goldman	Buy
2021-03-08	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-15	Downgrade	H.C. Wainwright	Buy → Neutral
2020-10-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-22	Iniziato	Mizuho	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-02-26	Reiterato	Oppenheimer	Outperform
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-10-01	Iniziato	Stifel	Buy
2019-04-29	Iniziato	Piper Jaffray	Overweight
2019-02-28	Reiterato	Chardan Capital Markets	Buy
2019-02-07	Iniziato	Robert W. Baird	Outperform
2018-12-31	Ripresa	B. Riley FBR	Buy
2018-07-06	Reiterato	Chardan Capital Markets	Buy
2018-04-10	Aggiornamento	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Reiterato	B. Riley FBR, Inc.	Neutral
2018-02-23	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Reiterato	H.C. Wainwright	Buy
2017-11-01	Reiterato	B. Riley FBR, Inc.	Buy

Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

Mar 27, 2025

Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - StockTitan

Mar 27, 2025

Mar 25, 2025

Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey

Mar 25, 2025

Mar 22, 2025

1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street - MSN

Mar 22, 2025

3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not - The Motley Fool

Mar 22, 2025

Mar 21, 2025

Iovance Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com

Mar 21, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Mar 21, 2025

Iovance Expands Team: 308,710 Stock Options Awarded as Growth Accelerates - StockTitan

Mar 21, 2025

Mar 18, 2025

Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha

Mar 18, 2025

Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor's budget address - Technical.ly

Mar 18, 2025

Mar 17, 2025

Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey

Mar 17, 2025

Stifel maintains Buy on Iovance Biotherapeutics stock, $18 target By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 12, 2025

Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? - Yahoo

Mar 12, 2025

Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR

Mar 12, 2025

Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 12, 2025

Mar 10, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Given New $19.00 Price Target at The Goldman Sachs Group - MarketBeat

Mar 06, 2025

Mar 05, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% After Analyst Downgrade - Defense World

Mar 05, 2025

Mar 04, 2025

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance - Yahoo Finance

Mar 04, 2025

Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan - Yahoo Finance

Mar 04, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group - Defense World

Mar 04, 2025

Mar 03, 2025

Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating - Marketscreener.com

Mar 03, 2025

Rhumbline Advisers Has $2.86 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 03, 2025

Iovance Biotherapeutics’ (IOVA) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025

Research Analysts Set Expectations for IOVA Q1 Earnings - Defense World

Mar 03, 2025

Mar 02, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St

Mar 02, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low After Analyst Downgrade - Defense World

Mar 02, 2025

Mar 01, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Given "Buy" Rating at HC Wainwright - MarketBeat

Mar 01, 2025

Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance UK

Mar 01, 2025

Robert W. Baird Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $20.00 - MarketBeat

Mar 01, 2025

Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World

Mar 01, 2025

Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN

Mar 01, 2025

Feb 28, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Hits Expectations - MarketBeat

Feb 28, 2025

Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks

Feb 28, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Meets Estimates - MarketBeat

Feb 28, 2025

New York State Common Retirement Fund Sells 98,840 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Feb 28, 2025

Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics - Benzinga

Feb 28, 2025

Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade) - Seeking Alpha

Feb 28, 2025

Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating - Marketscreener.com

Feb 28, 2025

IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty - Yahoo Finance

Feb 28, 2025

IOVA stock touches 52-week low at $3.92 amid market challenges By Investing.com - Investing.com South Africa

Feb 28, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises -February 28, 2025 at 03:51 am EST - Marketscreener.com

Feb 28, 2025